BioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to “Buy” at Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other analysts have also commented on the company. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wedbush cut their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Finally, Citizens Jmp increased their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $9.82 on Friday. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.22. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.56. The firm’s fifty day moving average price is $9.71 and its two-hundred day moving average price is $9.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period last year, the company earned $0.15 earnings per share. The business’s revenue was up 33.6% on a year-over-year basis. On average, research analysts forecast that BioCryst Pharmaceuticals will post -2.25 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Larson Financial Group LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $52,000. Pallas Capital Advisors LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $101,000. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals during the third quarter worth $77,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in BioCryst Pharmaceuticals during the second quarter worth $103,000. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.